Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous subcutaneous frusemide for decompensated heart failure
ACTRN12612000477820Phase 4Recruiting
- Sponsor
- Auckland City Hospital
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of furosemide in heart failure (HF), sponsored by Auckland City Hospital. Primary endpoints: Net urine volume voided, Urine sodium concentration and 4 more. Started May 2012; status: recruiting.
02
Drugs
furosemide
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on ACTRN12612000477820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000477820.